• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Celcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/25 4:34:44 PM ET
    $CELC
    Medical Specialities
    Health Care
    Get the next $CELC alert in real time by email
    false 0001603454 0001603454 2025-05-14 2025-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 14, 2025

     

    Celcuity Inc.

    (Exact name of Registrant as Specified in its Charter)

     

    Delaware   001-38207   82-2863566

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    16305 36th Avenue North; Suite 100

    Minneapolis, Minnesota 55446

    (Address of Principal Executive Offices and Zip Code)

     

    (763) 392-0767

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.001 par value per share   CELC   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition.

     

    On May 14, 2025, Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the first quarter ended March 31, 2025. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

     

    The information in this Item 2.02, including the accompanying exhibit, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in this Item 2.02 shall not be incorporated into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    99.1   Press release dated May 14, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 14, 2025

     

      CELCUITY INC.
         
      By /s/ Brian F. Sullivan
        Brian F. Sullivan
        Chief Executive Officer

     

     

     

     

    Get the next $CELC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CELC

    DatePrice TargetRatingAnalyst
    7/22/2024$29.00Outperform
    Leerink Partners
    2/22/2024$40.00Buy
    Stifel
    12/8/2023$27.00Buy
    H.C. Wainwright
    10/8/2021$50.00Buy
    Canaccord Genuity
    9/7/2021$48.00Buy
    Jefferies
    7/29/2021Outperform
    Cowen
    7/27/2021$50.00Buy
    Needham
    More analyst ratings

    $CELC
    Leadership Updates

    Live Leadership Updates

    See more
    • Celcuity Appoints Eldon Mayer as Chief Commercial Officer

      MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio

      2/20/24 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

      Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity's Board of DirectorsMINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors."We are delighted to welcome Dr. Murphy to our Board and look forward to leveraging her business development expertise and broad industry experience as we continue to advance our pipeline," said Brian Sullivan, CEO and Co-Founder of Celcuity.Dr. Murphy joins Cel

      9/14/22 9:00:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development

      MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced the addition of two senior executives to its corporate management team. Michael Snitkovsky joined Celcuity as VP of Program Management and David Bridge joined as VP of Quality Assurance and Process Development."We are pleased to welcome Michael and David to the Celcuity leadership team. Each brings extensive experience across the biopharmaceutical development spectrum, and each has a fantastic track record," said Brian Sullivan, Celcuity's Chief Executive O

      11/29/21 5:00:00 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Celcuity with a new price target

      Leerink Partners initiated coverage of Celcuity with a rating of Outperform and set a new price target of $29.00

      7/22/24 7:18:40 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Stifel initiated coverage on Celcuity with a new price target

      Stifel initiated coverage of Celcuity with a rating of Buy and set a new price target of $40.00

      2/22/24 6:21:40 AM ET
      $CELC
      Medical Specialities
      Health Care
    • H.C. Wainwright initiated coverage on Celcuity with a new price target

      H.C. Wainwright initiated coverage of Celcuity with a rating of Buy and set a new price target of $27.00

      12/8/23 7:38:12 AM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Dalvey David

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/21/25 4:49:35 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Director Buller Richard E was granted 1,029 shares, increasing direct ownership by 95% to 2,108 units (SEC Form 4)

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/21/25 4:48:37 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Nigon Richard

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/21/25 4:47:49 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

      SC 13G/A - Celcuity Inc. (0001603454) (Subject)

      11/14/24 5:46:12 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

      SC 13G/A - Celcuity Inc. (0001603454) (Subject)

      11/14/24 5:46:16 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Celcuity Inc.

      SC 13G - Celcuity Inc. (0001603454) (Subject)

      11/14/24 4:26:12 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    SEC Filings

    See more
    • SEC Form 8-K filed by Celcuity Inc.

      8-K - Celcuity Inc. (0001603454) (Filer)

      5/16/25 5:00:15 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Celcuity Inc.

      10-Q - Celcuity Inc. (0001603454) (Filer)

      5/15/25 5:00:26 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Celcuity Inc. (0001603454) (Filer)

      5/14/25 4:34:44 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Financials

    Live finance-specific insights

    See more
    • Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

      The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in the fourth quarter of 2025 VIKTORIA-2 Phase 3 trial remains on track to dose its first patient in the second quarter of 2025Initiating a clinical trial collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancerApproximately $206 million in cash, cash e

      5/14/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

      MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information  To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this

      5/7/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025Presented encouraging preliminary overall survival data from the Phase 1b study evaluating gedatolisib in combination with palbociclib and endocrine therapy at the 2024 SABCSApproximately $235.1 million in cash, cash equivalents and short-term investments at end of Q4 2024 expected to fund current clinical development program activities through 2026 Management to host webcast and conference call today, March 31, 2025, at 4:30 p.m. ET MINNEAPOLIS, March 31, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a c

      3/31/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

      MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit at 9:30 a.m. ET on Wednesday, May 28, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/cowen180/celc/1978947; andA fireside chat at the Jefferies Global Healthcare Conference at 7:35 a.m. ET on Thursday, June 5, 2025. A live webc

      5/21/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

      The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in the fourth quarter of 2025 VIKTORIA-2 Phase 3 trial remains on track to dose its first patient in the second quarter of 2025Initiating a clinical trial collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancerApproximately $206 million in cash, cash e

      5/14/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

      MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information  To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this

      5/7/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care